Logo image of NVAX

NOVAVAX INC (NVAX) Stock Fundamental Analysis

NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD

7.09  -0.11 (-1.53%)

After market: 7.1023 +0.01 (+0.17%)

Fundamental Rating

4

Taking everything into account, NVAX scores 4 out of 10 in our fundamental rating. NVAX was compared to 559 industry peers in the Biotechnology industry. While NVAX is still in line with the averages on profitability rating, there are concerns on its financial health. NVAX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year NVAX was profitable.
In the past year NVAX has reported a negative cash flow from operations.
In the past 5 years NVAX always reported negative net income.
NVAX had negative operating cash flow in 4 of the past 5 years.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

NVAX has a Return On Assets of 37.02%. This is amongst the best in the industry. NVAX outperforms 98.93% of its industry peers.
With an excellent Return On Invested Capital value of 38.36%, NVAX belongs to the best of the industry, outperforming 99.64% of the companies in the same industry.
Industry RankSector Rank
ROA 37.02%
ROE N/A
ROIC 38.36%
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

NVAX has a better Profit Margin (38.14%) than 98.21% of its industry peers.
NVAX's Operating Margin of 33.69% is amongst the best of the industry. NVAX outperforms 98.21% of its industry peers.
The Gross Margin of NVAX (87.52%) is better than 90.34% of its industry peers.
Industry RankSector Rank
OM 33.69%
PM (TTM) 38.14%
GM 87.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

NVAX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for NVAX has been increased compared to 1 year ago.
Compared to 5 years ago, NVAX has more shares outstanding
NVAX has a worse debt/assets ratio than last year.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

NVAX has an Altman-Z score of -1.89. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX has a Altman-Z score (-1.89) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.89
ROIC/WACC3.95
WACC9.71%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

NVAX has a Current Ratio of 2.06. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.06, NVAX is doing worse than 74.42% of the companies in the same industry.
NVAX has a Quick Ratio of 2.03. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
NVAX's Quick ratio of 2.03 is on the low side compared to the rest of the industry. NVAX is outperformed by 73.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 2.03
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 173.50% over the past year.
The Revenue has grown by 25.92% in the past year. This is a very strong growth!
NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.31% yearly.
EPS 1Y (TTM)173.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%379.05%
Revenue 1Y (TTM)25.92%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%610.3%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.84% on average per year.
The Revenue is expected to decrease by -10.43% on average over the next years. This is quite bad
EPS Next Y251.87%
EPS Next 2Y49.43%
EPS Next 3Y21.86%
EPS Next 5Y17.84%
Revenue Next Year53.15%
Revenue Next 2Y-12.41%
Revenue Next 3Y-26.24%
Revenue Next 5Y-10.43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

NVAX is valuated cheaply with a Price/Earnings ratio of 3.04.
Compared to the rest of the industry, the Price/Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 99.28% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.55, NVAX is valued rather cheaply.
NVAX is valuated rather expensively with a Price/Forward Earnings ratio of 18.45.
Based on the Price/Forward Earnings ratio, NVAX is valued cheaper than 93.20% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.40, NVAX is valued at the same level.
Industry RankSector Rank
PE 3.04
Fwd PE 18.45
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

99.64% of the companies in the same industry are more expensive than NVAX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.38
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

NVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 21.86% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y49.43%
EPS Next 3Y21.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVAVAX INC

NASDAQ:NVAX (6/11/2025, 8:04:29 PM)

After market: 7.1023 +0.01 (+0.17%)

7.09

-0.11 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners60.5%
Inst Owner Change-3.66%
Ins Owners0.35%
Ins Owner Change22.03%
Market Cap1.15B
Analysts78.46
Price Target17 (139.77%)
Short Float %31.44%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)124.28%
Min EPS beat(2)-58.31%
Max EPS beat(2)306.88%
EPS beat(4)2
Avg EPS beat(4)53.44%
Min EPS beat(4)-58.31%
Max EPS beat(4)306.88%
EPS beat(8)5
Avg EPS beat(8)21.96%
EPS beat(12)6
Avg EPS beat(12)-34.55%
EPS beat(16)6
Avg EPS beat(16)-60.38%
Revenue beat(2)2
Avg Revenue beat(2)46.34%
Min Revenue beat(2)2.61%
Max Revenue beat(2)90.08%
Revenue beat(4)3
Avg Revenue beat(4)23.46%
Min Revenue beat(4)-11.17%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)20.39%
Revenue beat(12)6
Avg Revenue beat(12)7.16%
Revenue beat(16)6
Avg Revenue beat(16)-2.44%
PT rev (1m)0%
PT rev (3m)-5.66%
EPS NQ rev (1m)-123.23%
EPS NQ rev (3m)-110.11%
EPS NY rev (1m)216.99%
EPS NY rev (3m)354.94%
Revenue NQ rev (1m)-4.95%
Revenue NQ rev (3m)-20.78%
Revenue NY rev (1m)45.53%
Revenue NY rev (3m)117.13%
Valuation
Industry RankSector Rank
PE 3.04
Fwd PE 18.45
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.38
EPS(TTM)2.33
EY32.86%
EPS(NY)0.38
Fwd EY5.42%
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS7.75
BVpS-0.47
TBVpS-1.16
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 37.02%
ROE N/A
ROCE 48.55%
ROIC 38.36%
ROICexc 239.72%
ROICexgc 1222.82%
OM 33.69%
PM (TTM) 38.14%
GM 87.52%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.48
Cap/Depr 16.56%
Cap/Sales 0.59%
Interest Coverage 22.06
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.06
Quick Ratio 2.03
Altman-Z -1.89
F-Score5
WACC9.71%
ROIC/WACC3.95
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)173.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%379.05%
EPS Next Y251.87%
EPS Next 2Y49.43%
EPS Next 3Y21.86%
EPS Next 5Y17.84%
Revenue 1Y (TTM)25.92%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%610.3%
Revenue Next Year53.15%
Revenue Next 2Y-12.41%
Revenue Next 3Y-26.24%
Revenue Next 5Y-10.43%
EBIT growth 1Y211.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year320.34%
EBIT Next 3Y13.61%
EBIT Next 5YN/A
FCF growth 1Y73.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.02%
OCF growth 3YN/A
OCF growth 5YN/A